BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27479820)

  • 41. Hodgkin Lymphoma: Diagnosis and Treatment.
    Ansell SM
    Mayo Clin Proc; 2015 Nov; 90(11):1574-83. PubMed ID: 26541251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
    Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
    Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
    Das-Gupta E; Thomson KJ; Bloor AJC; Clark AD; Mackinnon S; Kayani I; Clifton-Hadley L; Patrick P; El-Mehidi N; Lawrie A; Kirkwood AA; Russell NH; Linch DC; Peggs KS
    Blood Adv; 2019 Dec; 3(24):4264-4270. PubMed ID: 31869413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
    Chan TSY; Hwang YY; Khong PL; Leung AYH; Chim CS; Tse EWC; Kwong YL
    Hematol Oncol; 2020 Dec; 38(5):726-736. PubMed ID: 32786092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases.
    Gualco G; Natkunam Y; Bacchi CE
    Mod Pathol; 2012 May; 25(5):661-74. PubMed ID: 22222636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing.
    Cho J; Yoon SE; Kim SJ; Ko YH; Kim WS
    BMC Cancer; 2021 Aug; 21(1):972. PubMed ID: 34461835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
    Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma.
    Drees EEE; Roemer MGM; Groenewegen NJ; Perez-Boza J; van Eijndhoven MAJ; Prins LI; Verkuijlen SAWM; Tran XM; Driessen J; Zwezerijnen GJC; Stathi P; Mol K; Karregat JJJP; Kalantidou A; Vallés-Martí A; Molenaar TJ; Aparicio-Puerta E; van Dijk E; Ylstra B; Groothuis-Oudshoorn CGM; Hackenberg M; de Jong D; Zijlstra JM; Pegtel DM
    J Extracell Vesicles; 2021 Jul; 10(9):e12121. PubMed ID: 34295456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
    Trkulja KL; Manji F; Kuruvilla J; Laister RC
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
    Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
    Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
    Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
    Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
    Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
    Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.
    Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Pozzi S; Ferrari A; Baldini L; Gobbi P; Aviv A; Pugliese G; Federico M; Polliack A; Sacchi S
    Hematol Oncol; 2017 Dec; 35(4):561-566. PubMed ID: 27791277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
    Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
    Gunawardana J; Chan FC; Telenius A; Woolcock B; Kridel R; Tan KL; Ben-Neriah S; Mottok A; Lim RS; Boyle M; Rogic S; Rimsza LM; Guiter C; Leroy K; Gaulard P; Haioun C; Marra MA; Savage KJ; Connors JM; Shah SP; Gascoyne RD; Steidl C
    Nat Genet; 2014 Apr; 46(4):329-35. PubMed ID: 24531327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
    Schmitz R; Hansmann ML; Bohle V; Martin-Subero JI; Hartmann S; Mechtersheimer G; Klapper W; Vater I; Giefing M; Gesk S; Stanelle J; Siebert R; Küppers R
    J Exp Med; 2009 May; 206(5):981-9. PubMed ID: 19380639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.